Cytek Biosciences, Inc. (CTKB)

NASDAQHealth CareMedical - DevicesSnapshot 2026-10-23

$5.59+2.95%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Cytek Biosciences, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q4
Revenue	—	63.65M
EPS	—	-0.02
FY 2026 · Annual
Revenue	$207M–$212M	209.19M
EPS	—	-0.343
FY 2027 · Annual
Revenue	—	222.74M
EPS	—	-0.257

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Increase gross profit above $21.3M in Q1	A supporting condition in Cytek Biosciences, Inc.'s published investment case. The stated target is Gross profit rises above $21.3M quarterly.	Intact	Gross profit falls below $21.3M quarterly in 2026	Gross profit: $28.34M FY2026-Q2; GAAP. Published target: Gross profit rises above $21.3M quarterly. Target period is not explicitly aligned with this observation. Source published Aug 5, 202628,340,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: e81ea38b-622b-4d6f-9e97-15468c12380c. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Improve operating income from -$18.5M in Q1	A primary condition in Cytek Biosciences, Inc.'s published investment case. The stated target is Operating loss narrows from -$18.5M in Q1 2026.	Under Pressure	Operating loss worsens beyond -$18.5M in 2026	Operating income: $-11.4M FY2026-Q2; GAAP. Published target: Operating loss narrows from -$18.5M in Q1 2026. Target period is not explicitly aligned with this observation. Source published Aug 5, 2026-11,400,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: e81ea38b-622b-4d6f-9e97-15468c12380c. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Operating losses increased from $10.6 million in 2025-Q2 to $11.4 million in 2026-Q2, and from $15.0 million in 2025-Q1 to $18.5 million in 2026-Q1, indicating operating income has declined despite management focus. The trajectory shows limited progress on improving operating income. Delivery assessment Oct 24, 2026
Achieve 2026 revenue of $205M to $212M	A primary condition in Cytek Biosciences, Inc.'s published investment case. The stated target is ~$208.5M.	Improving	Annual revenue falls below $205M in 2026	Revenue: $48.14M FY2026-Q2; GAAP. Published target: ~$208.5M. Target period is not explicitly aligned with this observation. Source published Aug 5, 202648,140,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: e81ea38b-622b-4d6f-9e97-15468c12380c. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 4 of last 4 quarters. Full year 2025 revenue was $201.5 million, and management has guided 2026 revenue to $205 million to $212 million, raising the midpoint by $1 million in 2026-Q2. The trajectory shows consistent reaffirmation and modest growth expectations, indicating delivery aligned with stated guidance. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenue: comparable history unavailable.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	Unavailable	1 / 4
2026-07-25	Unavailable	Unavailable	1 / 4
2026-07-26	Unavailable	Unavailable	1 / 4
2026-07-27	Unavailable	Unavailable	1 / 4
2026-07-28	Unavailable	Unavailable	1 / 4
2026-07-29	Unavailable	Unavailable	1 / 3
2026-07-30	Unavailable	Unavailable	1 / 3
2026-07-31	Unavailable	Unavailable	1 / 4
2026-08-01	Unavailable	Unavailable	1 / 3
2026-08-02	Unavailable	Unavailable	1 / 4
2026-08-03	Unavailable	Unavailable	1 / 4
2026-08-04	Unavailable	Unavailable	1 / 3
2026-08-05	Unavailable	Unavailable	1 / 3
2026-08-06	Unavailable	Unavailable	1 / 4
2026-08-07	Unavailable	Unavailable	1 / 3
2026-08-08	Unavailable	Unavailable	1 / 4
2026-08-09	Unavailable	Unavailable	1 / 4
2026-08-10	Unavailable	Unavailable	1 / 4
2026-08-11	Unavailable	Unavailable	1 / 4
2026-08-12	Unavailable	Unavailable	1 / 3
2026-08-13	Unavailable	Unavailable	1 / 4
2026-08-14	Unavailable	Unavailable	1 / 3
2026-08-15	Unavailable	Unavailable	1 / 3
2026-08-16	Unavailable	Unavailable	1 / 3
2026-08-17	Unavailable	Unavailable	1 / 3
2026-08-18	Unavailable	Unavailable	1 / 3
2026-08-19	Unavailable	Unavailable	1 / 3
2026-08-20	Unavailable	Unavailable	1 / 3
2026-08-21	Unavailable	Unavailable	1 / 3
2026-08-22	Unavailable	Unavailable	1 / 3
2026-08-23	Unavailable	Unavailable	1 / 3
2026-08-24	Unavailable	Unavailable	1 / 3
2026-08-25	Unavailable	Unavailable	1 / 3
2026-08-26	Unavailable	Unavailable	1 / 3
2026-08-27	Unavailable	Unavailable	1 / 3
2026-08-28	Unavailable	Unavailable	1 / 3
2026-08-29	Unavailable	Unavailable	1 / 3
2026-08-30	Unavailable	Unavailable	1 / 3
2026-08-31	Unavailable	Unavailable	1 / 3
2026-09-01	Unavailable	Unavailable	1 / 3
2026-09-02	Unavailable	Unavailable	1 / 3
2026-09-03	Unavailable	Unavailable	1 / 3
2026-09-04	Unavailable	Unavailable	1 / 3
2026-09-05	Unavailable	Unavailable	1 / 3
2026-09-06	Unavailable	Unavailable	1 / 3
2026-09-07	Unavailable	Unavailable	1 / 3
2026-09-08	Unavailable	Unavailable	1 / 3
2026-09-09	Unavailable	Unavailable	1 / 3
2026-09-10	Unavailable	Unavailable	1 / 3
2026-09-11	Unavailable	Unavailable	1 / 3
2026-09-12	Unavailable	Unavailable	1 / 3
2026-09-13	Unavailable	Unavailable	1 / 3
2026-09-14	Unavailable	Unavailable	1 / 3
2026-09-15	Unavailable	Unavailable	1 / 3
2026-09-16	Unavailable	Unavailable	1 / 3
2026-09-17	Unavailable	Unavailable	1 / 3
2026-09-18	Unavailable	Unavailable	1 / 3
2026-09-19	Unavailable	Unavailable	1 / 3
2026-09-20	Unavailable	Unavailable	1 / 3
2026-09-21	Unavailable	Unavailable	1 / 3
2026-09-22	Unavailable	Unavailable	1 / 3
2026-09-23	Unavailable	Unavailable	1 / 3
2026-09-24	Unavailable	Unavailable	1 / 3
2026-09-25	Unavailable	Unavailable	1 / 3
2026-09-26	Unavailable	Unavailable	1 / 3
2026-09-27	Unavailable	Unavailable	1 / 3
2026-09-28	Unavailable	Unavailable	1 / 3
2026-09-29	Unavailable	Unavailable	1 / 3
2026-09-30	Unavailable	Unavailable	1 / 3
2026-10-01	Unavailable	Unavailable	1 / 3
2026-10-02	Unavailable	Unavailable	1 / 3
2026-10-03	Unavailable	Unavailable	1 / 3
2026-10-04	Unavailable	Unavailable	1 / 3
2026-10-05	Unavailable	Unavailable	1 / 3
2026-10-06	Unavailable	Unavailable	1 / 3
2026-10-07	Unavailable	Unavailable	1 / 3
2026-10-08	Unavailable	Unavailable	1 / 3
2026-10-09	Unavailable	Unavailable	1 / 3
2026-10-10	Unavailable	Unavailable	1 / 3
2026-10-11	Unavailable	Unavailable	1 / 3
2026-10-12	Unavailable	Unavailable	1 / 3
2026-10-13	Unavailable	Unavailable	1 / 3
2026-10-14	Unavailable	Unavailable	1 / 3
2026-10-15	Unavailable	Unavailable	1 / 3
2026-10-16	Unavailable	Unavailable	1 / 3
2026-10-17	Unavailable	Unavailable	1 / 3
2026-10-18	Unavailable	Unavailable	1 / 3
2026-10-19	Unavailable	Unavailable	1 / 3
2026-10-20	Unavailable	Unavailable	1 / 3
2026-10-21	Unavailable	Unavailable	1 / 3
2026-10-22	Unavailable	Unavailable	1 / 3
2026-10-23	Unavailable	Unavailable	2 / 2
2026-10-24	Unavailable	Unavailable	2 / 2

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	2	2
2026-06-01	2	2
2026-07-01	2	2
2026-08-01	2	2
2026-09-01	2	2
2026-10-01	2	2

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 2 Buy / Strong Buy · 2 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

StephensOct 23 · prior May 13

$4.75 → $6.00+26.3%

$0$3.30$6.60

1 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Increase gross profit above $21.3M in Q1Gross profit: $28.34M
Improve operating income from -$18.5M in Q1Published status: Under Pressure
Achieve 2026 revenue of $205M to $212MRevenue: $48.14M

Next proof point

Nov 4, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.6%Typical daily move · historical

Downside history

-42.9%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Cytek Biosciences, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a higher-risk growth business with some recurring-revenue characteristics, not yet a proven earnings compounder because it is loss-making. The long-term thesis is in a watch state: management has maintained growth priorities, but recent performance has been weak relative to its industry cohort.

What's priced into Cytek Biosciences, Inc.

CTKB trades at a durable premium to peers, and the valuation evidence describes it as expensive. The expectations gap is negative, which suggests current expectations may be ahead of what the fundamentals support; the priced-in signal is tagged as justified, with low fragility.

What the fundamentals likely do

Near term, revenue guidance calls for modest growth, and recurring revenue has risen to 35% of total revenue in each of the first two 2026 quarters. Instrument placements have also grown, but recent financial performance is weak, the company has missed earnings, and the next report carries elevated miss risk. Management’s record is stable, though a guidance cut after the recent increase would weaken confidence in execution.

What Cytek Biosciences, Inc. hinges on

Over the next few quarters, the central test is whether CTKB delivers its 2026 revenue guidance and keeps expanding placements and recurring revenue. A guidance reversal or further weakening in jobs data would add pressure, while continued strong results and guidance from healthcare sector bellwethers could support the sector backdrop.